

Get the latest on the Quillivant XR shortage in 2026. Learn what's causing it, whether it's still going on, and how to find your medication.
If you've been affected by the Quillivant XR shortage, you're not imagining things — and it's not over yet. Since 2023, patients and caregivers across the United States have struggled to find this essential ADHD medication at their pharmacies.
In this update, we'll cover the current status of the shortage, what's behind it, how much Quillivant XR costs in 2026, and the best strategies for finding it in stock.
Yes. As of early 2026, Quillivant XR remains listed on the FDA's drug shortage database and the ASHP (American Society of Health-System Pharmacists) shortage list. While supply has improved somewhat from the worst periods in 2023 and 2024, availability is still inconsistent across the country.
Some pharmacies may have intermittent stock, while others report being unable to order it at all. The situation varies significantly by region and by pharmacy wholesaler.
The Quillivant XR shortage is driven by several overlapping factors:
Quillivant XR is produced exclusively by Tris Pharma in New Jersey. As a specialty liquid formulation, it requires a complex reconstitution process and specialized manufacturing. When Tris Pharma experienced production disruptions, the entire national supply was affected because there's no other manufacturer making this product.
The ADHD stimulant shortage that started with Adderall in late 2022 created a domino effect across the entire market. As patients switched from amphetamine-based products to methylphenidate-based ones, demand for drugs like Quillivant XR, Concerta, and Ritalin surged beyond supply capacity.
As a Schedule II controlled substance, methylphenidate production is subject to DEA manufacturing quotas. These quotas limit how much raw methylphenidate can be produced annually, making it difficult for manufacturers to quickly scale up during periods of high demand.
There is no generic version of Quillivant XR available in pharmacies as of 2026. Without generic manufacturers producing the same product, the supply depends entirely on a single manufacturer.
The cost of Quillivant XR without insurance ranges from approximately $328 to $480 per bottle (120 mL), depending on the pharmacy.
Here are some ways to reduce costs:
For a detailed breakdown of savings options, see our guide on how to save money on Quillivant XR.
While there haven't been new liquid methylphenidate products approved recently, patients do have some options that may not have been available or considered previously:
Discuss these options with your prescriber, especially if the shortage continues. You can read more in our alternatives guide.
Even during a shortage, Quillivant XR does become available at pharmacies periodically. Here's how to maximize your chances:
For more detailed strategies, read our post on how to find Quillivant XR in stock near you.
The Quillivant XR shortage has been one of the most persistent challenges in the broader ADHD medication supply crisis. In 2026, the medication is still in shortage, still expensive without help, and still the only long-acting liquid methylphenidate on the market.
But there are tools and strategies that can help. Medfinder puts real-time pharmacy data at your fingertips, savings programs can dramatically reduce costs, and your prescriber can guide you through alternatives if needed.
Stay informed. For more, visit our posts on why Quillivant XR is hard to find and what Quillivant XR is and how it works.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.